GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Beneish M-Score

Regenxbio (Regenxbio) Beneish M-Score : -3.59 (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Regenxbio's Beneish M-Score or its related term are showing as below:

RGNX' s Beneish M-Score Range Over the Past 10 Years
Min: -4.35   Med: -1.24   Max: 19.31
Current: -3.59

During the past 11 years, the highest Beneish M-Score of Regenxbio was 19.31. The lowest was -4.35. And the median was -1.24.


Regenxbio Beneish M-Score Historical Data

The historical data trend for Regenxbio's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenxbio Beneish M-Score Chart

Regenxbio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.31 -1.06 -0.23 -1.41 -3.59

Regenxbio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.41 -1.68 -2.34 -1.08 -3.59

Competitive Comparison of Regenxbio's Beneish M-Score

For the Biotechnology subindustry, Regenxbio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenxbio's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Regenxbio's Beneish M-Score falls into.



Regenxbio Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Regenxbio for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0862+0.528 * 0.8783+0.404 * 0.3201+0.892 * 0.8006+0.115 * 0.7121
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2962+4.679 * -0.098273-0.327 * 1.4071
=-3.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $26.34 Mil.
Revenue was 22.213 + 28.914 + 19.977 + 19.138 = $90.24 Mil.
Gross Profit was 10.975 + 16.526 + 10.502 + 15.026 = $53.03 Mil.
Total Current Assets was $334.97 Mil.
Total Assets was $573.97 Mil.
Property, Plant and Equipment(Net PPE) was $192.59 Mil.
Depreciation, Depletion and Amortization(DDA) was $17.32 Mil.
Selling, General, & Admin. Expense(SGA) was $88.49 Mil.
Total Current Liabilities was $130.27 Mil.
Long-Term Debt & Capital Lease Obligation was $82.22 Mil.
Net Income was -62.889 + -61.868 + -72.061 + -66.676 = $-263.49 Mil.
Non Operating Income was 2.366 + 4.66 + 2.127 + 2.166 = $11.32 Mil.
Cash Flow from Operations was -40.76 + -49.407 + -47.322 + -80.918 = $-218.41 Mil.
Total Receivables was $30.29 Mil.
Revenue was 31.345 + 26.512 + 32.649 + 22.218 = $112.72 Mil.
Gross Profit was 18.562 + 13.418 + 19.698 + 6.501 = $58.18 Mil.
Total Current Assets was $415.98 Mil.
Total Assets was $833.27 Mil.
Property, Plant and Equipment(Net PPE) was $206.80 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.91 Mil.
Selling, General, & Admin. Expense(SGA) was $85.28 Mil.
Total Current Liabilities was $130.43 Mil.
Long-Term Debt & Capital Lease Obligation was $88.80 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(26.341 / 90.242) / (30.292 / 112.724)
=0.291893 / 0.268727
=1.0862

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(58.179 / 112.724) / (53.029 / 90.242)
=0.516119 / 0.587631
=0.8783

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (334.971 + 192.59) / 573.97) / (1 - (415.976 + 206.801) / 833.268)
=0.080856 / 0.252609
=0.3201

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=90.242 / 112.724
=0.8006

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(12.909 / (12.909 + 206.801)) / (17.32 / (17.32 + 192.59))
=0.058755 / 0.082512
=0.7121

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(88.494 / 90.242) / (85.281 / 112.724)
=0.98063 / 0.756547
=1.2962

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((82.222 + 130.272) / 573.97) / ((88.802 + 130.434) / 833.268)
=0.370218 / 0.263104
=1.4071

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-263.494 - 11.319 - -218.407) / 573.97
=-0.098273

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Regenxbio has a M-score of -3.59 suggests that the company is unlikely to be a manipulator.


Regenxbio Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Regenxbio's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenxbio (Regenxbio) Business Description

Traded in Other Exchanges
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
Executives
Kenneth T. Mills director, officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Steve Pakola officer: Chief Medical Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Allan M. Fox director, 10 percent owner C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas officer: Senior VP, General Counsel C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Curran Simpson officer: SVP of Technical Operations C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos officer: Chief Scientific Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo officer: Chief Medical Officer C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Daniel Tasse director C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809